{"transactions":[{"id":700615,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":27748,"kind":"organization","name":"RTW Fund Group GP, LLC","position":1,"cik":"0002147397","reported_name":"RTW Fund Group GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-07-30T20:05:03.000Z","date":"2026-07-29","kind":"other","planned":false,"acquired":true,"shares":133290,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Exchange Agreement, dated as of July 29, 2026, RTW Entity (as defined below) exchanged 133,290 shares of the Issuer's common\nstock for pre-funded warrants to purchase an equivalent number of shares of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by a certain affiliated entity (\"RTW Entity\") managed by RTW Fund Group GP, LLC (\"RTW Fund Group\"). Roderick Wong, M.D. serves as the Managing Member of RTW Fund Group. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":8949719,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":133290},"source":{"system":"sec-edgar","filing":"0001104659-26-088665","document":"tm2621459-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000110465926088665/tm2621459-14_4seq1.xml","form_type":"4"}},{"id":700614,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":27748,"kind":"organization","name":"RTW Fund Group GP, LLC","position":1,"cik":"0002147397","reported_name":"RTW Fund Group GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-30T20:05:03.000Z","date":"2026-07-29","kind":"other","planned":false,"acquired":false,"shares":133290,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Exchange Agreement, dated as of July 29, 2026, RTW Entity (as defined below) exchanged 133,290 shares of the Issuer's common\nstock for pre-funded warrants to purchase an equivalent number of shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by a certain affiliated entity (\"RTW Entity\") managed by RTW Fund Group GP, LLC (\"RTW Fund Group\"). Roderick Wong, M.D. serves as the Managing Member of RTW Fund Group. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":266307,"source":{"system":"sec-edgar","filing":"0001104659-26-088665","document":"tm2621459-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000110465926088665/tm2621459-14_4seq1.xml","form_type":"4"}},{"id":703990,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":true,"shares":1771,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Held by an Other RTW Fund."}],"balance_after":1771,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1771},"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703989,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":true,"shares":19934,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On July 21, 2026, RTW  Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW  Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of  the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On July 21, 2026, RTW  Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW  Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of  the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by RTW Biotech Fund."}],"balance_after":19934,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":19934},"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703988,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":true,"shares":161807,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for  161,807 shares of  the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for  161,807 shares of  the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by RTW Innovation."}],"balance_after":161807,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":161807},"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703987,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":true,"shares":209254,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 21, 2026, RTW Master Fund, Ltd. (\"Master Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a \"Pre-Funded Warrant\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2026, RTW Master Fund, Ltd. (\"Master Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a \"Pre-Funded Warrant\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Master Fund."}],"balance_after":209254,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":209254},"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703986,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":false,"shares":1771,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Held by an Other RTW Fund."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703985,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":false,"shares":19934,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On July 21, 2026, RTW  Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW  Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of  the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On July 21, 2026, RTW  Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW  Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of  the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by RTW Biotech Fund."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703984,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":false,"shares":161807,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for  161,807 shares of  the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for  161,807 shares of  the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by RTW Innovation."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":703983,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2026-07-23T21:10:27.000Z","date":"2026-07-21","kind":"other","planned":false,"acquired":false,"shares":209254,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 21, 2026, RTW Master Fund, Ltd. (\"Master Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a \"Pre-Funded Warrant\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2026, RTW Master Fund, Ltd. (\"Master Fund\") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a \"Pre-Funded Warrant\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. (\"RTW Innovation\"), RTW Biotech Opportunities Operating Ltd. (\"RTW Biotech Fund\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Master Fund."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001231919-26-000786","document":"form4-07232026_090723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000786/form4-07232026_090723.xml","form_type":"4"}},{"id":715171,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-07T00:00:01.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":78960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 78,960 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027."}],"balance_after":78960,"derivative":{"exercise_price":3.35,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":78960},"source":{"system":"sec-edgar","filing":"0001140361-26-027681","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036126027681/form4.xml","form_type":"4"}},{"id":715170,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-07T00:00:01.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":27832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027."}],"balance_after":75499,"source":{"system":"sec-edgar","filing":"0001140361-26-027681","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036126027681/form4.xml","form_type":"4"}},{"id":798006,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-04-29T21:36:43.000Z","date":"2026-04-27","kind":"other","planned":false,"acquired":false,"shares":1250032,"price":2.7499,"value":3437462.9968,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the RTW Funds shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the RTW Funds, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer\nfollowing such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the RTW Funds shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the RTW Funds, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer\nfollowing such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds (the \"RTW Funds\") managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":2386331,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1250032},"source":{"system":"sec-edgar","filing":"0001231919-26-000427","document":"form4-04292026_090438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000123191926000427/form4-04292026_090438.xml","form_type":"4"}},{"id":798005,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T21:36:43.000Z","date":"2026-04-27","kind":"sale","planned":false,"acquired":false,"shares":32,"price":4.13,"value":132.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds (the \"RTW Funds\") managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":9556063,"source":{"system":"sec-edgar","filing":"0001231919-26-000427","document":"form4-04292026_090438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000123191926000427/form4-04292026_090438.xml","form_type":"4"}},{"id":798004,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T21:36:43.000Z","date":"2026-04-27","kind":"other","planned":false,"acquired":true,"shares":1250032,"price":0.0001,"value":125.0032,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds (the \"RTW Funds\") managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":9556095,"source":{"system":"sec-edgar","filing":"0001231919-26-000427","document":"form4-04292026_090438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000123191926000427/form4-04292026_090438.xml","form_type":"4"}},{"id":802767,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2026820,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2026820},"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802766,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":8250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8250000},"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802765,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":10776820,"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802764,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":10276820,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":10276820,"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":1000155,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":96896,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by an Other RTW Fund."}],"balance_after":96896,"derivative":{"exercise_price":1.67,"underlying":"Common Stock","underlying_shares":96896},"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1000154,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":767848,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by RTW Innovation."}],"balance_after":767848,"derivative":{"exercise_price":1.67,"underlying":"Common Stock","underlying_shares":767848},"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1000153,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":991544,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Warrant is exercisable following receipt of the Stockholder Approval (as defined herein) at an exercise price of $1.67 per share and terminates on the five year anniversary of the date of the Stockholder Approval. The holder of the Warrant may not exercise such Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Issuer is required to use its reasonable best efforts to hold a meeting of stockholders no later than January 31, 2026 for the purpose of, among other things, obtaining stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the Warrants (the \"Stockholder Approval\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Master Fund."}],"balance_after":991544,"derivative":{"exercise_price":1.67,"underlying":"Common Stock","underlying_shares":991544},"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1000152,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":96896,"price":1.67,"value":161816.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by an Other RTW Fund."}],"balance_after":298992,"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1000151,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":767848,"price":1.67,"value":1282306.16,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by RTW Innovation."}],"balance_after":2427089,"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1000150,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-13T22:26:01.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":991544,"price":1.67,"value":1655878.48,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Persons acquired the shares of Common Stock and Warrants in a private placement by the Issuer.  The purchase price per share of Common Stock and accompanying Warrant was $1.67 per share and accompanying Warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Master Fund."}],"balance_after":3138798,"source":{"system":"sec-edgar","filing":"0001231919-25-000468","document":"form4-11132025_101154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000468/form4-11132025_101154.xml","form_type":"4"}},{"id":1004863,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"price":126839,"reported_value":126839,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by an Other RTW Fund."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":37863},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004862,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"price":126839,"reported_value":126839,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by an Other RTW Fund."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":37863},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004861,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"price":2117044,"reported_value":2117044,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RTW Innovation."}],"balance_after":0,"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":631954},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004860,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"price":2117044,"reported_value":2117044,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RTW Innovation."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":631954},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004859,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"price":2756117,"reported_value":2756117,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Master Fund."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":822722},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004858,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"price":2756117,"reported_value":2756117,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 5, 2025, pursuant to the terms of that certain Note Purchase Agreement dated April 14, 2024 as amended through April 15, 2025 (the \"Amended Note Purchase Agreement\"), the Reporting Persons delivered, and the Issuer accepted, conversion notices to convert $5.0 million aggregate principal amount of the convertible senior secured notes (the \"Notes\") held by the Reporting Persons at the floor conversion price of $3.35 per share. The remaining outstanding amount of the Notes remains convertible at a conversion price of $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Amended Note Purchase Agreement, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Issuer's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Master Fund."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":822722},"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004857,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":37863,"price":3.35,"value":126841.05,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by an Other RTW Fund."}],"balance_after":202096,"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004856,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":631954,"price":3.35,"value":2117045.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by RTW Innovation."}],"balance_after":1659241,"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1004855,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-11-07T22:18:07.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":822722,"price":3.35,"value":2756118.7,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported herein, including RTW Master Fund, Ltd. (\"Master Fund\"), RTW Innovation Master Fund, Ltd. (\"RTW Innovation\") and other funds or accounts managed by the Adviser (each, an \"Other RTW Fund\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Master Fund."}],"balance_after":2147254,"source":{"system":"sec-edgar","filing":"0001231919-25-000449","document":"form4-11072025_101100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000123191925000449/form4-11072025_101100.xml","form_type":"4"}},{"id":1033707,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Equity Swap (obligation to buy)","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":17.8112,"underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033706,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Equity Swap (obligation to buy)","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":19.0916,"underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033705,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Equity Swap (obligation to buy)","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":40.0324,"underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033704,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":59000,"price":3.105,"value":183195.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18188457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033703,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":true,"shares":59000,"price":17.8112,"value":1050860.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18247457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033702,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":41000,"price":3.105,"value":127305.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18188457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033701,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":true,"shares":41000,"price":19.0916,"value":782755.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18229457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033700,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":false,"shares":1000000,"price":3.105,"value":3105000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18188457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1033699,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2025-09-23T20:21:23.000Z","date":"2025-09-19","kind":"other","planned":false,"acquired":true,"shares":1000000,"price":40.0324,"value":40032400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":19188457,"source":{"system":"sec-edgar","filing":"0001231919-25-000232","document":"form4-09232025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191925000232/form4-09232025_080918.xml","form_type":"4"}},{"id":1073171,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2025-08-06T20:28:01.000Z","date":"2025-08-04","kind":"purchase","planned":false,"acquired":true,"shares":3636363,"price":2.7499,"value":9999634.6137,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer\nfollowing such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer\nfollowing such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":3636363,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3636363},"source":{"system":"sec-edgar","filing":"0001415889-25-021173","document":"form4-08062025_080857.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000141588925021173/form4-08062025_080857.xml","form_type":"4"}},{"id":1084663,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-07-18T20:05:40.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":17667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026."}],"balance_after":47667,"source":{"system":"sec-edgar","filing":"0001140361-25-026412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036125026412/form4.xml","form_type":"4"}},{"id":1084662,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-07-18T20:05:40.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  The RSUs will vest in full on June 18, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  The RSUs will vest in full on June 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  The RSUs will vest in full on June 18, 2026."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis.  The RSUs will vest in full on June 18, 2026."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001140361-25-026412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036125026412/form4.xml","form_type":"4"}},{"id":1162516,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T12:18:11.000Z","date":"2025-04-30","kind":"purchase","planned":false,"acquired":true,"shares":49900,"price":2.99,"value":149201.0,"ownership":{"direct":false,"nature":"Please see footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The reporting persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":8306063,"source":{"system":"sec-edgar","filing":"0001062993-25-008272","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000106299325008272/form4.xml","form_type":"4"}},{"id":1163940,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T21:16:34.000Z","date":"2025-04-29","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.53,"value":126500.0,"ownership":{"direct":false,"nature":"Please see footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The reporting persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":8256163,"source":{"system":"sec-edgar","filing":"0001062993-25-008205","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000106299325008205/form4.xml","form_type":"4"}},{"id":1169767,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-04-17T22:36:58.000Z","date":"2025-04-16","kind":"exercise","planned":false,"acquired":false,"price":5000000,"reported_value":5000000,"ownership":{"direct":false,"nature":"Please see footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On April 15, 2025, the conversion price of $5.0 million aggregate principal amount of the convertible senior secured notes held by the Reporting Persons (the \"Notes\") was amended from $40.50 per share to $3.35 per share.  The remaining outstanding amount of the Notes remain convertible at a conversion price $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Note Purchase Agreement, as amended, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Company's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported on this Form 3, including RTW Master Fund, Ltd. (\"Master Fund\") and RTW Innovation Master Fund, Ltd. (\"RTW Innovation,\" and, together with Master Fund and other funds or accounts managed by the Adviser, the \"RTW Funds\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by RTW Funds."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":1492539},"source":{"system":"sec-edgar","filing":"0001062993-25-007660","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000106299325007660/form4.xml","form_type":"4"}},{"id":1169766,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2025-04-17T22:36:58.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"price":5000000,"reported_value":5000000,"ownership":{"direct":false,"nature":"Please see footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On April 15, 2025, the conversion price of $5.0 million aggregate principal amount of the convertible senior secured notes held by the Reporting Persons (the \"Notes\") was amended from $40.50 per share to $3.35 per share.  The remaining outstanding amount of the Notes remain convertible at a conversion price $40.50 per share, as well as additional conversion prices in the discretion of the Issuer (the \"Discretionary Conversions\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes bear interest at an annual rate of 6.0%, which is payable quarterly in cash, or, at the Issuer's option, in kind for the first three years. The reported amount of shares does not give effect to any increase in principal amount as a result of PIK interest payments. The maturity date of the Notes is April 16, 2031. Pursuant to the Note Purchase Agreement, as amended, the RTW Funds may not convert the Notes to the extent that such conversion would result in the RTW Funds beneficially owning more than 9.99% of the Company's common stock after giving effect to such conversion, unless converted pursuant to a Discretionary Conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported on this Form 3, including RTW Master Fund, Ltd. (\"Master Fund\") and RTW Innovation Master Fund, Ltd. (\"RTW Innovation,\" and, together with Master Fund and other funds or accounts managed by the Adviser, the \"RTW Funds\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by RTW Funds."}],"derivative":{"exercise_price":3.35,"expiration_date":"2031-04-16","underlying":"Common Stock","underlying_shares":1492539},"source":{"system":"sec-edgar","filing":"0001062993-25-007660","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000106299325007660/form4.xml","form_type":"4"}},{"id":1169765,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-04-17T22:36:58.000Z","date":"2025-04-16","kind":"exercise","planned":false,"acquired":true,"shares":37863,"price":3.35,"value":126841.05,"ownership":{"direct":false,"nature":"Please see footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported on this Form 3, including RTW Master Fund, Ltd. (\"Master Fund\") and RTW Innovation Master Fund, Ltd. (\"RTW Innovation,\" and, together with Master Fund and other funds or accounts managed by the Adviser, the \"RTW Funds\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by RTW Funds."}],"balance_after":164233,"source":{"system":"sec-edgar","filing":"0001062993-25-007660","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000106299325007660/form4.xml","form_type":"4"}},{"id":1169764,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-04-17T22:36:58.000Z","date":"2025-04-16","kind":"exercise","planned":false,"acquired":true,"shares":631954,"price":3.35,"value":2117045.9,"ownership":{"direct":false,"nature":"Please see footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported on this Form 3, including RTW Master Fund, Ltd. (\"Master Fund\") and RTW Innovation Master Fund, Ltd. (\"RTW Innovation,\" and, together with Master Fund and other funds or accounts managed by the Adviser, the \"RTW Funds\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by RTW Innovation."}],"balance_after":1027287,"source":{"system":"sec-edgar","filing":"0001062993-25-007660","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000106299325007660/form4.xml","form_type":"4"}},{"id":1169763,"issuer":{"id":8577,"kind":"organization","name":"ALLURION TECHNOLOGIES, INC."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73214,"kind":"person","name":"RTW Innovation Master Fund Ltd.","position":4,"cik":"0001776733","reported_name":"RTW Innovation Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-04-17T22:36:58.000Z","date":"2025-04-16","kind":"exercise","planned":false,"acquired":true,"shares":822722,"price":3.35,"value":2756118.7,"ownership":{"direct":false,"nature":"Please see footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RTW Investments, LP (the \"Adviser\") manages certain funds that directly hold the securities reported on this Form 3, including RTW Master Fund, Ltd. (\"Master Fund\") and RTW Innovation Master Fund, Ltd. (\"RTW Innovation,\" and, together with Master Fund and other funds or accounts managed by the Adviser, the \"RTW Funds\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by Master Fund."}],"balance_after":1324532,"source":{"system":"sec-edgar","filing":"0001062993-25-007660","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000106299325007660/form4.xml","form_type":"4"}},{"id":1330779,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2024-12-17T00:38:22.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":12.49,"value":4996000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Pre-Funded Warrant was purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after December 12, 2024, exercise the Pre-Funded Warrant until exercised in full. The Pre-Funded Warrant reported herein contains an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrant until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrant beneficially owned by the Reporting Persons is not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after December 12, 2024, exercise the Pre-Funded Warrant until exercised in full. The Pre-Funded Warrant reported herein contains an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrant until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrant beneficially owned by the Reporting Persons is not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":3526955,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001062993-24-020690","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000106299324020690/form4.xml","form_type":"4"}},{"id":1473139,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:10:30.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":3325,"price":15.04,"value":50008.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 3,325 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000."}],"balance_after":3325,"derivative":{"exercise_price":22.86,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":3325},"source":{"system":"sec-edgar","filing":"0001140361-24-030729","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036124030729/form4.xml","form_type":"4"}},{"id":1473138,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:10:30.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":23944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025."}],"balance_after":23944,"derivative":{"exercise_price":22.86,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":23944},"source":{"system":"sec-edgar","filing":"0001140361-24-030729","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036124030729/form4.xml","form_type":"4"}},{"id":1679089,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, par value $0.001 per share (\"Common Stock\")","published_at":"2024-01-16T21:20:17.000Z","date":"2024-01-12","kind":"other","planned":false,"acquired":false,"shares":1842499,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The RTW Funds (as defined below) exchanged 1,842,499 shares of Common Stock for 1,842,499 pre-funded warrants pursuant to an Exchange Agreement, dated as of January 12, 2024, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one share of Common Stock for an exercise price of $0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Common Stock underlying the pre-funded warrants reported on this Form 4 are subject to a lock-up agreement among the RTW Funds and J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, dated October 30, 2023, pursuant to which the shares of common stock underlying the pre-funded warrants reported herein cannot be sold until May 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The RTW Funds (as defined below) exchanged 1,842,499 shares of Common Stock for 1,842,499 pre-funded warrants pursuant to an Exchange Agreement, dated as of January 12, 2024, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one share of Common Stock for an exercise price of $0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":5175832,"source":{"system":"sec-edgar","filing":"0000902664-24-000237","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266424000237/ownership.xml","form_type":"4"}},{"id":1777293,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2023-09-19T20:15:51.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":3126955,"price":15.99,"value":50000010.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 15, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after September 15, 2023, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":3126955,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":3126955},"source":{"system":"sec-edgar","filing":"0000902664-23-004827","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004827/ownership.xml","form_type":"4"}},{"id":1793012,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Equity Swap (obligation to sell)","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":22.05,"exercise_date":"2018-08-27","expiration_date":"2023-08-28","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1793011,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Equity Swap (obligation to buy)","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the \"2018 Form 4\"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the \"2018 Form 4\"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":22.05,"exercise_date":"2018-08-27","expiration_date":"2023-08-28","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1793010,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":true,"shares":500000,"price":15.87,"value":7935000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18157605,"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1793009,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":500000,"price":22.05,"value":11025000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 28, 2023, the equity swap entered into by RTW Master Fund, Ltd. previously reported on the 2018 Form 4, expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Master Fund, Ltd. into an equity swap (obligation to buy); RTW Master Fund, Ltd. in fact entered into an equity swap (obligation to sell)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":17657605,"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1793008,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":500000,"price":15.87,"value":7935000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the \"2018 Form 4\"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18157605,"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1793007,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.01 par value (\"Common Stock\")","published_at":"2023-08-30T20:15:19.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":true,"shares":500000,"price":22.05,"value":11025000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 28, 2023, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Form 4 filed by the Reporting Persons on August 29, 2018 (the \"2018 Form 4\"), expired and settled in accordance with its terms. The 2018 Form 4 reported the entry by RTW Innovation Master Fund, Ltd. into an equity swap (obligation to sell); RTW Innovation Master Fund, Ltd. in fact entered into an equity swap (obligation to buy)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18657605,"source":{"system":"sec-edgar","filing":"0000902664-23-004651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423004651/ownership.xml","form_type":"4"}},{"id":1844178,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T23:48:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":3590,"price":13.93,"value":50008.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 3,590 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000."}],"balance_after":3590,"derivative":{"exercise_price":21.56,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":3590},"source":{"system":"sec-edgar","filing":"0001140361-23-031531","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036123031531/form4.xml","form_type":"4"}},{"id":1844177,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T23:48:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":25850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024."}],"balance_after":25850,"derivative":{"exercise_price":21.56,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":25850},"source":{"system":"sec-edgar","filing":"0001140361-23-031531","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036123031531/form4.xml","form_type":"4"}},{"id":1902954,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T13:11:08.000Z","date":"2023-04-13","kind":"other","planned":false,"acquired":true,"shares":502133,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 20, 2023, Orchestra BioMed Holdings, Inc. (the \"Issuer\") formally notified the reporting persons that they are entitled to receive 502,133 additional shares of the Issuer's common stock pursuant to an \"earn-out\" provision in the agreement and plan of merger, dated as of July 4, 2022, as amended (the \"Merger Agreement\"). The Merger Agreement provided that certain stockholders of Orchestra BioMed, Inc. would receive their pro-rata portion of additional shares of the Issuer's common stock, for no additional consideration, if the volume-weighted average price of the Issuer's common stock is greater than or equal to $15.00 per share over any twenty trading days within any thirty-trading day period (the \"Initial Milestone Event\") within a specified time-period. The Issuer reported that the Initial Milestone Event was satisfied on April 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 20, 2023, Orchestra BioMed Holdings, Inc. (the \"Issuer\") formally notified the reporting persons that they are entitled to receive 502,133 additional shares of the Issuer's common stock pursuant to an \"earn-out\" provision in the agreement and plan of merger, dated as of July 4, 2022, as amended (the \"Merger Agreement\"). The Merger Agreement provided that certain stockholders of Orchestra BioMed, Inc. would receive their pro-rata portion of additional shares of the Issuer's common stock, for no additional consideration, if the volume-weighted average price of the Issuer's common stock is greater than or equal to $15.00 per share over any twenty trading days within any thirty-trading day period (the \"Initial Milestone Event\") within a specified time-period. The Issuer reported that the Initial Milestone Event was satisfied on April 12, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"), and Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW.  The reporting person disclaims beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein."}],"balance_after":5620645,"source":{"system":"sec-edgar","filing":"0001062993-23-010266","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000106299323010266/form4.xml","form_type":"4"}},{"id":1925050,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2023-04-05T20:31:11.000Z","date":"2022-12-01","kind":"other","planned":false,"acquired":true,"shares":61705,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Acquired pursuant to the Merger Agreement in exchange for warrants to purchase 350,000 shares of Renovacor common stock on the effective date of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired pursuant to the Merger Agreement in exchange for warrants to purchase 350,000 shares of Renovacor common stock on the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":61705,"derivative":{"exercise_price":65.23,"expiration_date":"2026-09-02","underlying":"Common Stock","underlying_shares":30852},"source":{"system":"sec-edgar","filing":"0000902664-23-002478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002478/ownership.xml","form_type":"4"}},{"id":1925049,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Equity Swap (obligation to buy)","published_at":"2023-04-05T20:31:11.000Z","date":"2022-05-19","kind":"other","planned":false,"acquired":true,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 19, 2022, the expiration date of the equity swaps previously reported on the Form 4 filed by the Reporting Persons on May 13, 2021, was extended from September 16, 2024 to September 16, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":1000000,"derivative":{"exercise_price":40.0324,"underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000902664-23-002478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002478/ownership.xml","form_type":"4"}},{"id":1925048,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.01 par value (\"Common Stock\")","published_at":"2023-04-05T20:31:11.000Z","date":"2022-12-01","kind":"other","planned":false,"acquired":true,"shares":529038,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022 (the \"Merger Agreement\"), by and among, Rocket Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\"), Renovacor, Inc., a Delaware corporation ( \"Renovacor\"), and the other parties thereto, in exchange for 3,000,803 shares of Renovacor common stock on the effective date of the merger contemplated by the Merger Agreement (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":18157605,"source":{"system":"sec-edgar","filing":"0000902664-23-002478","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002478/ownership.xml","form_type":"4"}},{"id":1925046,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-04-05T20:30:43.000Z","date":"2022-12-01","kind":"other","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for 61,705 Rocket warrants to purchase 30,852 shares of Rocket common stock on the effective date of the Merger."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for 61,705 Rocket warrants to purchase 30,852 shares of Rocket common stock on the effective date of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for 61,705 Rocket warrants to purchase 30,852 shares of Rocket common stock on the effective date of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for 61,705 Rocket warrants to purchase 30,852 shares of Rocket common stock on the effective date of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for 61,705 Rocket warrants to purchase 30,852 shares of Rocket common stock on the effective date of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000902664-23-002477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002477/ownership.xml","form_type":"4"}},{"id":1925045,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-04-05T20:30:43.000Z","date":"2022-12-01","kind":"other","planned":false,"acquired":false,"shares":3000803,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022, by and among Rocket Pharmaceuticals, Inc., a Delaware corporation (\"Rocket\") and Renovacor, Inc., a Delaware corporation (the \"Issuer\") and the other parties thereto (the \"Merger Agreement\") in exchange for 529,038 shares of Rocket common stock on the effective date of the merger contemplated by the Merger Agreement (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022, by and among Rocket Pharmaceuticals, Inc., a Delaware corporation (\"Rocket\") and Renovacor, Inc., a Delaware corporation (the \"Issuer\") and the other parties thereto (the \"Merger Agreement\") in exchange for 529,038 shares of Rocket common stock on the effective date of the merger contemplated by the Merger Agreement (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the securities held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000902664-23-002477","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002477/ownership.xml","form_type":"4"}},{"id":1939080,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value (\"Common Shares\")","published_at":"2023-03-24T20:30:34.000Z","date":"2023-03-22","kind":"other","planned":false,"acquired":false,"shares":1059000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The RTW Funds (as defined below) exchanged 1,059,000 Common Shares for 1,059,000 pre-funded warrants pursuant to an Exchange Agreement, dated as of March 22, 2023, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one Common Share for an exercise price of $0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The RTW Funds (as defined below) exchanged 1,059,000 Common Shares for 1,059,000 pre-funded warrants pursuant to an Exchange Agreement, dated as of March 22, 2023, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one Common Share for an exercise price of $0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to Common Shares held by certain investment funds managed by the Adviser (the \"RTW Funds\"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":3256102,"source":{"system":"sec-edgar","filing":"0000902664-23-002379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266423002379/ownership.xml","form_type":"4"}},{"id":2042270,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-30T22:11:42.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":2310000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 4,967,741 shares of Orchestra BioMed, Inc. (\"Orchestra\") common stock in connection with the merger of Orchestra into Health Sciences Acquisitions Corporation 2 (\"HSAC 2\"), renamed upon closing \"Orchestra BioMed Holdings, Inc.\" (\"OBIO\") at an exchange ratio of 0.465 shares of ordinary shares of HSAC2/OBIO for each whole share of Orchestra common stock. On the effective date of the merger, the closing price of OBIO's common stock was $13.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 4,967,741 shares of Orchestra BioMed, Inc. (\"Orchestra\") common stock in connection with the merger of Orchestra into Health Sciences Acquisitions Corporation 2 (\"HSAC 2\"), renamed upon closing \"Orchestra BioMed Holdings, Inc.\" (\"OBIO\") at an exchange ratio of 0.465 shares of ordinary shares of HSAC2/OBIO for each whole share of Orchestra common stock. On the effective date of the merger, the closing price of OBIO's common stock was $13.31 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"), and Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW.  The reporting persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":5118512,"source":{"system":"sec-edgar","filing":"0001062993-23-001606","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000106299323001606/form4.xml","form_type":"4"}},{"id":2045085,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-26T22:23:34.000Z","date":"2023-01-24","kind":"purchase","acquired":true,"shares":1808512,"price":10,"value":18085120.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"), and Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW.  The reporting person disclaims beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein."}],"balance_after":2808512,"source":{"system":"sec-edgar","filing":"0001062993-23-001419","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000106299323001419/form4.xml","form_type":"4"}},{"id":2076731,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Notional Derivative Agreements (obligation to buy)","published_at":"2022-12-23T21:42:16.000Z","date":"2022-12-23","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $17.8112. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":1,"derivative":{"underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0000902664-22-005284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422005284/ownership.xml","form_type":"4"}},{"id":2077624,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Notional Derivative Agreements (obligation to buy)","published_at":"2022-12-22T23:33:23.000Z","date":"2022-12-22","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The RTW Funds (as defined below) entered into certain notional principal amount derivative agreements in the form of cash settled swaps with a reference price of $19.0916. The derivative agreements shall continue until terminated as elected by the parties and currently have an initial reference termination date of September 16, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":1,"derivative":{"underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000902664-22-005275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422005275/ownership.xml","form_type":"4"}},{"id":2122269,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-11-08T22:19:32.000Z","date":"2021-01-26","kind":"other","acquired":false,"shares":31450,"price":9.54,"value":300033.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of common stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":0,"derivative":{"exercise_price":9.54,"exercise_date":"2019-08-29","expiration_date":"2021-03-07","underlying":"Common Stock","underlying_shares":31450},"source":{"system":"sec-edgar","filing":"0000902664-22-004774","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004774/ownership.xml","form_type":"4"}},{"id":2122268,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T22:19:32.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":100000,"price":1.7666,"value":176660.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of common stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":3018666,"source":{"system":"sec-edgar","filing":"0000902664-22-004774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004774/ownership.xml","form_type":"4"}},{"id":2122267,"issuer":{"id":89998,"kind":"organization","name":"DermTech, Inc.","symbol":"DMTK"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-08T22:19:32.000Z","date":"2021-01-26","kind":"other","acquired":true,"shares":31450,"price":9.54,"value":300033.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of common stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":3118666,"source":{"system":"sec-edgar","filing":"0000902664-22-004774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004774/ownership.xml","form_type":"4"}},{"id":2139158,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.01 par value (\"Common Stock\")","published_at":"2022-10-11T20:31:31.000Z","date":"2022-10-06","kind":"purchase","acquired":true,"shares":1355932,"price":14.75,"value":19999997.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D. (\"Dr. Wong\"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors."}],"balance_after":17628567,"source":{"system":"sec-edgar","filing":"0000902664-22-004508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004508/ownership.xml","form_type":"4"}},{"id":2150500,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-27T20:30:27.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":300000,"price":0.69,"value":207000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of common stock held by certain investment funds managed by the Adviser (the \"RTW Funds\") and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":3975722,"source":{"system":"sec-edgar","filing":"0000902664-22-004363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004363/ownership.xml","form_type":"4"}},{"id":2162277,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-09-09T20:15:34.000Z","date":"2022-09-07","kind":"sale","acquired":false,"shares":1557346,"price":8.71,"value":13564483.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ordinary course rebalancing transactions in which certain RTW Funds (as defined below) rebalance holdings of the Issuer among the RTW Funds. After the transactions reported herein, the amount of Common Shares of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to Common Shares held by certain investment funds managed by the Adviser (the \"RTW Funds\"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":4315102,"source":{"system":"sec-edgar","filing":"0000902664-22-004219","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004219/ownership.xml","form_type":"4"}},{"id":2162276,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value (\"Common Shares\")","published_at":"2022-09-09T20:15:34.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":1557346,"price":8.71,"value":13564483.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ordinary course rebalancing transactions in which certain RTW Funds (as defined below) rebalance holdings of the Issuer among the RTW Funds. After the transactions reported herein, the amount of Common Shares of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to Common Shares held by certain investment funds managed by the Adviser (the \"RTW Funds\"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":4315102,"source":{"system":"sec-edgar","filing":"0000902664-22-004219","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422004219/ownership.xml","form_type":"4"}},{"id":2202856,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-25T12:45:31.000Z","date":"2022-07-22","kind":"purchase","acquired":true,"shares":1000000,"price":10.01,"value":10010000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed to be beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of securities held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the \"Funds\"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaims beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-22-041090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390022041090/ownership.xml","form_type":"4"}},{"id":2231450,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T01:07:22.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":5876,"price":6.8,"value":39956.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 5,876 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. This option was issued to the Reporting Person in lieu of director retainer fees of $40,000."}],"balance_after":5876,"derivative":{"exercise_price":10.77,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":5876},"source":{"system":"sec-edgar","filing":"0001140361-22-023148","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036122023148/form4.xml","form_type":"4"}},{"id":2231449,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T01:07:22.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":47745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023."}],"balance_after":47745,"derivative":{"exercise_price":10.77,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":47745},"source":{"system":"sec-edgar","filing":"0001140361-22-023148","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493280/000114036122023148/form4.xml","form_type":"4"}},{"id":2430472,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2022-01-20T22:00:25.000Z","date":"2022-01-18","kind":"purchase","acquired":true,"shares":44440,"price":8,"value":355520.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":3000803,"source":{"system":"sec-edgar","filing":"0000902664-22-000395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422000395/ownership.xml","form_type":"4"}},{"id":2434853,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T23:13:16.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":5723,"price":8,"value":45784.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":2956363,"source":{"system":"sec-edgar","filing":"0000902664-22-000269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422000269/ownership.xml","form_type":"4"}},{"id":2434852,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T23:13:16.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":145000,"price":7.9976,"value":1159652.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":2950640,"source":{"system":"sec-edgar","filing":"0000902664-22-000269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422000269/ownership.xml","form_type":"4"}},{"id":2434851,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T23:13:16.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":286,"price":7.75,"value":2216.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":2805640,"source":{"system":"sec-edgar","filing":"0000902664-22-000269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422000269/ownership.xml","form_type":"4"}},{"id":2434850,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2022-01-14T23:13:16.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":1950,"price":7.6703,"value":14957.085,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed by each of (i) RTW Investments, LP (the \"Adviser\") with respect to the shares of Common Stock held by certain investment funds managed by the Adviser and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser."}],"balance_after":2805354,"source":{"system":"sec-edgar","filing":"0000902664-22-000269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000090266422000269/ownership.xml","form_type":"4"}},{"id":2441483,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-07T00:43:55.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":51296,"price":8,"value":410368.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2803404,"source":{"system":"sec-edgar","filing":"0000902664-22-000093","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000093/ownership.xml","form_type":"4"}},{"id":2441482,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-07T00:43:55.000Z","date":"2022-01-05","kind":"purchase","acquired":true,"shares":100195,"price":7.9997,"value":801529.9415,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2752108,"source":{"system":"sec-edgar","filing":"0000902664-22-000093","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000093/ownership.xml","form_type":"4"}},{"id":2441481,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2022-01-07T00:43:55.000Z","date":"2022-01-04","kind":"purchase","acquired":true,"shares":3.932,"price":8,"value":31.456,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2651913,"source":{"system":"sec-edgar","filing":"0000902664-22-000093","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000093/ownership.xml","form_type":"4"}},{"id":2454403,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T02:09:18.000Z","date":"2022-01-03","kind":"purchase","acquired":true,"shares":441,"price":7.9501,"value":3505.9941,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2647981,"source":{"system":"sec-edgar","filing":"0000902664-22-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000009/ownership.xml","form_type":"4"}},{"id":2454402,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T02:09:18.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":3743,"price":8,"value":29944.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2647540,"source":{"system":"sec-edgar","filing":"0000902664-22-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000009/ownership.xml","form_type":"4"}},{"id":2454401,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2022-01-04T02:09:18.000Z","date":"2021-12-29","kind":"purchase","acquired":true,"shares":479,"price":8,"value":3832.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2643797,"source":{"system":"sec-edgar","filing":"0000902664-22-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266422000009/ownership.xml","form_type":"4"}},{"id":2457857,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-28T23:57:12.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":4905,"price":7.9936,"value":39208.608,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2643318,"source":{"system":"sec-edgar","filing":"0000902664-21-005405","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266421005405/ownership.xml","form_type":"4"}},{"id":2457856,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73213,"kind":"person","name":"RTW MASTER FUND, LTD.","position":3,"cik":"0001493219","reported_name":"RTW MASTER FUND, LTD.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2021-12-28T23:57:12.000Z","date":"2021-12-23","kind":"purchase","acquired":true,"shares":61584,"price":7.9725,"value":490978.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (the \"Adviser\"), which is deemed the beneficial owner of shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (collectively, the \"Funds\"), which are investment funds managed by the Adviser, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser. Dr. Wong exercises voting and dispositive control over the shares of Common Stock held by the Adviser and is therefore deemed to be a beneficial owner of securities owned or controlled by the Adviser."}],"balance_after":2638413,"source":{"system":"sec-edgar","filing":"0000902664-21-005405","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493219/000090266421005405/ownership.xml","form_type":"4"}}],"next_cursor":"2021-12-28T23:57:12.000000Z,2457856"}